期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

多发性硬化复发、缓解期血清MMP-9、TIMP-1含量的变化 被引量：3

The Changes of Serum MMP-9 and TIMP-1 Concentrations on the Acute Exacerbation Stage and the Remission Stage of Multiple Sclerosis
下载PDF
导出
摘要 目的探讨血清基质金属蛋白酶-9(MMP-9)及其组织抑制剂-1(TIMP-1)水平与缓解-复发型多发性硬化(RRMS)的关系并评价其临床意义。方法选择RRMS复发期患者28例、缓解期患者20例,并选择正常体检者30例为对照组。用酶联免疫吸附法(ELISA)检测血清MMP-9、TIMP-1水平,并进行统计学分析。结果 RRMS复发期患者血清MMP-9水平、MMP-9/TIMP-1比值较对照组显著升高(P<0.01),较缓解期患者也有明显升高(P<0.05),TIMP-1水平较对照组降低明显(P<0.05),但与缓解期患者比较差别无统计学意义(P=0.655)。RRMS复发期患者血清MMP-9水平、MMP-9/TIMP-1比值与EDSS评分无相关性。结论血清MMP-9含量、MMP-9/TIMP-1比值与RRMS的炎症活动密切相关,可作为监测RRMS活动性的血清学指标。 Objective To investigate the changes of serum MMP-9 and TIMP-1 concentrations and their correlations with expanded disability status scale（EDSS） on the acute exacerbation stage and the remission stage of multiple sclerosis. To explore their values in the evaluation of RRMS activity. Meth- ods 28 patients of RRMS in relapsing state （relapsing RRMS group）, 20 in remitting state （remitting RRMS group）and 30 healthy controls were enrolled. Their serum MMP-9 and TIMP-1 concentrations were detected by enzyme-linked-immunoassay （ELISA）. Results The MMP-9 serum level and the ratio of MMP-9/TIMP-1 of the relapsing RRMS group were significantly higher than that of the healthy control group （P 〈0.01） and the remitting RRMS group （P〈0.05）. The TIMP-1 serum level of the relapsing RRMS group was significantly lower than that of the healthy control group （P〈0.05） and had no signifi- cant difference with the remitting RRMS group （P=0. 655）. The MMP-9 serum level and the ratio of MMP-9/TIMP-1 of the relapsing RRMS group were not correlated with EDSS of MS. Conclusions The MMP-9 serum level and the ratio of MMP-9/TIMP-1 of the RRMS may be a biomarker reflecting the activ- ity of disease.
作者 叶励超 蔡若蔚 黄玉婷 钱加强 洪志林
机构地区 福建医科大学附属第二医院神经内科 福建医科大学附属第二医院检验科
出处 《福建医科大学学报》 2012年第3期196-198,共3页 Journal of Fujian Medical University
基金 泉州市技术研究与开发项目(2011Z41)
关键词 多发性硬化 复发缓解性 基金属蛋白酶-9 金属蛋白酶1组织抑制剂 multiple sclerosis, relapsing-remitting matrix metalloproteinase 9 tissue inhibitor of metalloproteinase-1
分类号 R744.51 [医药卫生—神经病学与精神病学]
  • 相关文献

参考文献12

  • 1Kurzepa J, Bartosik-psujek H, Suchozebrska-Jesionek D, et al.Role of matrix metallopmteinases in the pathogenesis of multi- ple sclerosis[J]. Neural Neumehlr Pol, 2005,39(1) : 63-67.
  • 2McDonald W I,Compston A,Edan G,et al. Recommended di- agnostic criteria for multiple sclerosis: guidelines from the in- ternational panel on the diagnosis of multiple sclerosis[J]. Ann Neurol, 2001,50(1) :121-127.
  • 3Polman C H, Reingold S C, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald eriteria [J]. AnnNeurol, 2011,69:292-302.
  • 4Kurtzke J F. Rating neurologie impairment in multiple sclero- sis: An expanded disability status seale(EDSS)[J]. Neurolo- gy, 1983,33(11) :1444-1452.
  • 5Yong V W,Zabad R K,Agrawal S,et al. Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators[J]. J Neurol Sci, 2007,259 (1-2) : 79-84.
  • 6Diaz-Sanebez M,Williams K, DeLuca G C, et al. Protein co-ex- pression with axonal injury in multiple sclerosis plaques[J]. Acts Neurepathol (Bed), 2006,111 (4) : 289-299.
  • 7Benesova Y, Vasku A, Novotna H, et al. Matrix metalloprotei- nase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis[J]. Mul Scler, 2009, 15 (3): 316-322.
  • 8Avolio C,Filippi M,Tortorella C,etal. Serum MMP-9/TIMP- 1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relation- ships with different magnetic resonance imaging measures of disease activity during IFN-beta-la treatment[J]. Mult Scler, 2008,11 (4) :441-446.
  • 9Boz C,Ozm enoglu M,Velioglu S,et al. Matrix metalloprotei- nase-9(MMP-9)and tissue inhibitor of matrix metalloprotein- ase(TIMP-1)in patients with relapsing-remitting multiple scle- rosis treated with interferon beta[J].Clin Neurol Neurosurg, 2006,108(2) : 124-128.
  • 10Minagar A,Alexander J S,Sehwendimann R N,et al. Combi- nation therapy with interferon beta-la and doxycycline in multiple sclerosis: an open-label trial [J]. Arch Neurol, 2008,65 : 199-204.

二级参考文献26

  • 1倪秀石,欧阳建,王翀,朱文辉.自体造血干细胞移植治疗多发性硬化引起不明原因进行性黄疸一例[J].江苏医药,2006,32(3):288-289. 被引量：2
  • 2Mezey E,Key S,Voqelsang G,et al.Transplanted bone marrowgenerates new neurons in human brains[J].Proc Natl Acad,2003,100(3):1364-1369.
  • 3Engelhardt B.Molecular mechanisms involved in T cell migration across the blood-brain barrier[J].Neural Transm,2006,113(4):477-485.
  • 4Einstein O,Fainstein N,Vaknin I,et al.Neural precursorsattenuate autoimmune encephalomyelitis by peripheral[J].Ann Neurol,2007,61(3):209-288.
  • 5Muraro P A,Douek D C.Renewing the T cell repertoire to arrest autoimmune aggression[J].Trends Immunol,2006,27(2):61-67.
  • 6Saccardi R,Kozak T,Bocelli-Tyndall C,et al.Autologous stem cell transplantation for progressive multiple sclerosis:update of the European group for blood and marrow transplantation autoimmune diseases working party database[J].Multiple Sclerosis,2006,12(6):814-823.
  • 7Ju Z,Jiang H,Jaworski M,et al.Telomere dysfunction induces environmental alterations limiting hematopoietic stem cell function and engraftment[J].Nature Medicine,2007,13(6):742-747.
  • 8Gladstone D E,Zamkoff K W,Krupp L,et al.High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis[J].Arch Neurol,2006,63(10):252-256.
  • 9Narayanasami U,Kanteti R,Morelli J,et al.Randomized trial of filgrastim versus chemotherapy and filgrastimmobilization of hematopoietic progenitor cells for rescue in autologous transplantation[J].Blood,2001,98(7):2059-2064.
  • 10Snira O,Lavie G,Achironc A,et al.G-CSF enhances the adhesion of encephalitogenic T cells to extracellular matrix components:A possible mechanism for exacerbation of multiple sclerosis[J].J Neuroimmunology,2006,172(1):145-155.

同被引文献45

  • 1Benjamin MM,Khalil RA.Metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease[J].EXS,2012,103:209-279.
  • 2Bruschi F,Pinto B.The significance of matrix metalloproteinases in parasitic infections involving the central nervous system[J].Pathogens,2013,2(1):105-129.
  • 3Verslegers M,Lemmens K,Van Hove I,et al.Matrix metalloproteinase-2 and-9 as promising benefactors in development,plasticity and repair of the nervous system[J].Prog Neurobiol,2013,105:60-78.
  • 4Cossins JA,Clements JM,Ford J,et al.Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions[J].Acta Neuropathol,1997,94(6):590-598.
  • 5Lindberg RL,DeGroot C J,Montagne L,et al.The expression profile of matrix metalloproteinases(MMPs) and their inhibitors(TIMPs) in lesions and norml appearing white matter of multiple sclerosis[J].Brain,2001,124(Pt 9):1743-1753.
  • 6Weaver A,Goncalves da Silva A,Nuttall RK,et al.An elevated matrix metalloproteinase(MMP) in an animal model of multiple sclerosis isprotective by affecting Th1/Th2 polarization[J].FASEB,2005,19(12):1668-16670.
  • 7H ansmann F,H erder V,Kalkuhl A,et al.Matrix metalloproteinase12 deficiency ameliorates the clinical course and demyelination inTheiler's murine encephalomyelitis[J].Acta Neuropathol,2012,124(1):127-142.
  • 8Yulmaz ü,Gücüyener K,Atak A,et al.Matrix metalloproteinase-7 and matrix metalloproteinase-9 in pediatric multiple sclerosis[J].Pediatr Neurol,2012,47(3):171-176.
  • 9Cox MB,Bowden NA,Scott RJ,et al.Altered expression of the plasminogen activation pathway in peripheral blood mononuclear cells in multiple sclerosis:possible pathomechanism of matrix metalloproteinase activation[J].Mult Scler,2013,19(10):1268-1274.
  • 10Buhler LA,Samara R,Guzman E,et al.Matrix metalloproteinase-7 facilitates immune access to the CNS in experimental autoimmune encephalomyelitis[J].BMC Neurosci,2009,10:17.

引证文献3

二级引证文献8

福建医科大学学报
2012年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部